Significance of platelet and AFP levels and liver function parameters for HCC size and survival

International Journal of Biological Markers

Volumn 29, Issue 3, 2014, Pages e215-e223

  Carr, Brian I ^a   Guerra, Vito ^a   Giannini, Edoardo G ^b   Farinati, Fabio ^c   Ciccarese, Francesca ^d   Rapaccini, Gian Ludovico ^e   Di Marco, Maria ^f   Benvegnù, Luisa ^c   Zoli, Marco ^g   Borzio, Franco ^h   Caturelli, Eugenio ⁱ   Chiaramonte, Maria ^j   Trevisani, Franco ^g  

^a NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d AO Desio Vimercate   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

^f BOLOGNINI HOSPITAL   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h FATEBENEFRATELLI HOSPITAL   (Italy)

ⁱ BELCOLLE HOSPITAL   (Italy)

^j SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; AFP PROTEIN, HUMAN;

AGED; ARTICLE; BLOOD CELL COUNT; CHILD PUGH SCORE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PORTAL VEIN THROMBOSIS; PROTHROMBIN TIME; RETROSPECTIVE STUDY; SURVIVAL; THROMBOCYTE; TUMOR VOLUME; BLOOD; CANCER STAGING; EPIDEMIOLOGY; INFORMATION PROCESSING; ITALY; LIVER TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSPECTIVE STUDY;

AGED; ALPHA-FETOPROTEINS; BLOOD PLATELETS; CARCINOMA, HEPATOCELLULAR; DATA COLLECTION; FEMALE; HUMANS; ITALY; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 84907501834     PISSN: 03936155     EISSN: 17246008     Source Type: Journal    
DOI: 10.5301/jbm.5000064     Document Type: Article

References (25)

1. Ringe B, Pichlmayr R, Wittekind C, Tusch G. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg. 1991; 15(2): 270-285.
2. Iwatsuki S, Starzl TE, Sheahan DG, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg. 1991; 214(3): 221-228, discussion 228-229.
3. Yoshizumi T, Ikegami T, Yoshiya S, et al. Impact of tumor size, number of tumors and neutrophil-to-lymphocyte ratio in liver transplantationfor recurrent hepatocellular carcinoma. Hepatol Res. 2013; 43(7): 709-16.
4. Adam R, Bhangui P, Vibert E, et al. Resection or transplantation for early hepatocellular carcinoma in a cirrhotic liver: does size define the best oncological strategy? Ann Surg. 2012; 256(6): 883-891.
5. Lu SN, Wang JH, Liu SL, et al. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer. 2006; 107(9): 2212-22.
6. Kumada T, Toyoda H, Kiriyama S, et al. Incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection who have normal alanine aminotransferase values. J Med Virol. 2010; 82(4): 539-545.
7. Lok AS, Seeff LB, Morgan TR, et al. HALT-C Trial Group. Incidence of hepatocellular carcinoma and associated riskfactorsin hepatitis C-related advanced liver disease. Gastroenterology. 2009; 136: 138-148.
8. Carr BI, Guerra V, Pancoska P. Thrombocytopenia in relation to tumor size in patients with hepatocellular carcinoma. Oncology. 2012; 83(6): 339-345.
9. Carr BI, Guerra V, De Giorgio M, Fagiuoli S, Pancoska P. Small hepatocellular carcinomas and thrombocytopenia. Oncology. 2012; 83(6): 331-338.
10. Riess L. Zur pathologischen anatomie des blutes. Arch. Anat. Physiol. Wissensch. Med. 1872; 39: 237-249.
11. Levin J, Conley CL. Thrombocytosis associated with malignant disease. Arch Intern Med. 1964; 114(4): 497-500.
12. Hwang SJ, Luo JC, Li CP, et al. Thrombocytosis: a paraneoplastic syndrome in patients with hepatocellular carcinoma. World J Gastroenterol. 2004; 10(17): 2472-2477.
13. Carr BI and Guerra B Thrombocytosis and HCC. Dig Dis Sci. 2013; 58(6): 1790-6.
14. Santi V, Buccione D, Di Micoli A, et al. The changing scenario of hepatocellular carcinoma over the last two decades in Italy. J Hepatol. 2012; 56(2): 397-405.
15. Sherman M. Alphafetoprotein: an obituary. J Hepatol. 2001; 34(4): 603-605.
16. Izumi M. Isolation, characterization and clinical evaluation of the gamma-glutamyltransferase associatedwith hepatocellular carcinoma. Acta Med Okayama. 1985; 39: 19-33.
17. Xu K, Meng XY, Wu JW, Shen B, Shi YC, Wei Q. Diagnostic value of serum gamma-glutamyl transferase isoenzyme for hepatocellular carcinoma: a 10-year study. Am J Gastroenterol. 1992; 87(8): 991-995.
18. Carr BI, Pancoska P, Branch RA. Low alpha-fetoprotein hepatocellular carcinoma. J Gastroenterol Hepatol. 2010; 25(9): 1543-1549.
19. Yu MC, Chan KM, Lee CF, et al. Alkaline phosphatase: does it have a role in predicting hepatocellular carcinoma recurrence? J Gastrointest Surg. 2011; 15(8): 1440-1449.
20. Nowatari T, Fukunaga K, Ohkohchi N. Regulation of signal transduction and role of platelets in Liver Regeneration Int. J Hepatol. 2012; 2012: 542479.
21. Sitia G, Aiolfi R, Di Lucia P, et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci USA. 2012; 109(32): E2165-E2172.
22. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med. 2008; 359(19): 1995-2004.
23. Utsunomiya T, Shimada M, Imura S, Morine Y, Ikemoto T, Mori M. Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma. J Gastroenterol. 2010; 45(2): 146-152.
24. Pancoska P, Carr BI, Branch RA. Network-based analysis of survival for unresectable hepatocellular carcinoma. Semin Oncol. 2010; 37(2): 170-181.
25. Yang JD, Nakamura I, Roberts LR. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol. 2011; 21(1): 35-43.